Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management strategies. While bypassing agents such as FEIBA and NovoSeven have historically been the primary go-to therapies, the landscape has been transformed by the launch of Hemlibra, which has redefined the standard of care for prophylaxis. The hemophilia A inhibitor market is entering a new era of disruption with the introduction of Alhemo (concizumab) and Qfitlia (fitusiran), which promise to decrease treatment burdens. Furthermore, the potential for immune tolerance induction (ITI) protocols to be used alongside novel non-factor therapies remains a critical, evolving discussion among hematologists. Understanding how hematologists navigate balancing bleed protection with the risks of thrombotic events and the high cost of care is vital for hemophilia A treatment. This report provides a comprehensive analysis of the hemophilia A inhibitor treatment landscape, with insights into the shifting treatment dynamics.
QUESTIONS ANSWERED
- How are current treatment patterns evolving for hemophilia A patients with inhibitors across the United States?
- How do factors such as mode of drug administration, drug delivery, or formulary access influence choice of therapy?
- How is patient share distributed among leading therapies, and how stable are these patterns over time?
- What will be the impact of novel agents such as Qfitlia and Alhemo for the hemophilia A with inhibitors market?
CONTENT HIGHLIGHTS
Geographies: United States.
Primary research: Survey of 101 hematologists.
Key drugs covered: Hemlibra, Alhemo, Qfitlia, Factor VIII replacement therapies, FEIBA, NovoSeven, Sevenfact.
PRODUCT DESCRIPTION
Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
- Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.
